Trump’s administration entered into an agreement with AstraZeneca for late-stage and large scale manufacture of AZD7442, a combination of two monoclonal antibodies that treats or prevents SARS-CoV-2, according to press release. AZD7442 use is crucial to people with weak immune system, those over 80 years, and patients undergoing treatments that preclude them from using COVID-19 vaccine.
- The U.S. Department of Health and Human Services (HHS) and Department of Defense (DoD) to provide about $ 486 million to AstraZeneca for two phase 3 clinical trials and development activities of AZD7442.
- HHS is supporting promising monoclonal antibodies for prevention and treatment, including supply, to allow faster distributions after successful trials
- Working together across clinical development and manufacturing supply to accelerate the product development timelines
Pharmaceutical stocks gaining on vaccine developments. LLY: NYSE is up 2.20%, AZN is up 0.17%, REGN: NASDAQ is up 0.37%
